Document:

Exhibit 10.21  

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED AS "(CONFIDENTIAL TREATMENT REQUESTED)" IN THE TEXT, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Terms and Conditions for the Manufacture of Products by Ben Venue Laboratories, Inc  

This
signed agreement is required to provide services and manufacture your Product at Ben Venue Laboratories, Inc. This agreement covers all Products & services for the development and
manufacture of Products for your company at Ben Venue and remains in place until superceded by a formal supply agreement. 

By: 

Ben
Venue Laboratories, Inc.

300 Northfield Road

Bedford, Ohio 44146 

Hereinafter
referred to as BVL, and 

CUSTOMER
NAME

ADDRESS

CITY, STATE, ZIP 

Hereinafter
referred to as Customer, 

agree
to the following terms and conditions in reference to the development and manufacture of Customer's Products at BVL. 

1.     Facilities  

1.1
BVL will provide manufacturing facilities that conform to current Good Manufacturing Practices established by the FDA and will perform its obligations hereunder and supply Product in accordance
with all applicable laws and regulations and in accordance with written documentation provided to Customer. 

1.2
All services will be performed at BVL facilities unless otherwise agreed to in writing by BVL and Customer. 

2.     Audits  

2.1
Customer and any third-party consultant appointed by Customer shall have reasonable access to observe and inspect BVL's facilities and procedures with respect to the Products
including all analytical and manufacturing documentation directly related to the Products upon scheduling in advance with BVL's compliance manager. Any such Customer appointed
third-party consultant must be pre-approved by BVL such approval not to be unreasonably withheld and be bound in writing to the Confidentiality Agreement signed by Customer and BVL.
Customer shall have the right to one annual compliance audit each year to (i) observe, inspect and audit the manner in which BVL conducts quality control of Customer Products,
(ii) inspect BVL's plant and records relating to BVL's quality and other controls related to its manufacture of the Products. For cause audits will be scheduled as
mutually agreed to by the parties. 

2.2
Customer's employees and/or representatives including consultants who inspect BVL facilities shall comply with all BVL policies and procedures. Customer assumes all liability resulting from
presence of Customer's employees at BVL facilities, except to the extent that any such liability is a result of BVL's negligence or willful misconduct. 

3.     Materials & Documentation  

3.1
Customer will provide active drug substance and any other mutually agreed to Customer supplied components at (CONFIDENTIAL TREATMENT REQUESTED) in advance of scheduled manufacturing date in
accordance with BVL's procedures. 

3.2
Customer must give BVL permission in writing to do ID only by label verification of the active drug substance, if no identification test is to be performed at BVL. 

3.3
BVL will release all materials provided by BVL. 

3.4
Customer will provide materials and manufacturing information necessary for the development and manufacturing of Products. 

3.5
Customer will specify samples to be sent for testing and provide address for shipment on the purchase order for all sample request not included in the Master Production Record. 

3.6
BVL will provide, at Customer's request, a copy of the BVL Drug Master File (DMF) and authorization for FDA to access the DMF. This may be used by the Customer to prepare a Regulatory filing. 

3.7
BVL shall deliver Product and/or Services to Customer in compliance with quotations provided to Customer which shall be referenced by quotation number on Customer's purchase order, which shall
include by reference specifications mutually agreed upon by the Customer and BVL. For manufacturing services said specifications must be incorporated in the master batch record or in a special
instruction to a specific batch record. 

3.8
BVL will submit to Customer a Certificate of Compliance, a Certificate of Analysis listing results of testing, and a completed batch record for each lot of Product shipped. 

3.9
Customer will provide written QC testing requirements, methods, specifications and reference standard for the Active Pharmaceutical Ingredient and drug Product. Customer will approve initial
testing documents, the Master Production Record and any revisions of the documents thereafter. Revisions of approved documents requested within eight weeks of scheduled manufacturing or other services
may cause a delay or postponement of manufacturing and/or other services requested by the Customer. 

3.10
Customer is responsible for notifying BVL with instruction for disposition of tailings and rejects, which will be incorporated into the Master Batch Record and include a shipment address for
tailing and rejects if Customer requests return of tailings and rejects. 

3.11
Customer will evaluate BVL Certificate of Analysis and perform at least an identity assay upon all batches of Product manufactured for the Customer. 

3.12
Customer will be financially responsible for all materials purchased by BVL on Customer's behalf based on requirements communicated by Customer to BVL in forecast and/or Purchase Orders, in the
event the materials become obsolete for any reason, including but not limited to termination of the project by Customer for any reason. 

4.     Purchase Orders  

4.1
Customer will provide Purchase Orders with information defined in Item 4.2 (CONFIDENTIAL TREATMENT REQUESTED) in advance of the requested manufacturing date or (CONFIDENTIAL TREATMENT REQUESTED)
in advance of the requested delivery date. Purchase Orders for other services will be issued by the Customer on a mutually agreed upon timeline with BVL. All purchase orders will reference the BVL
quotation number(s) provided to Customer. 

4.2
The following information must be included on all Purchase Orders 

4.2.1
BVL end item number or description of service outlined in the Quotation provided to Customer 

4.2.2
BVL Product description or service description 

4.2.3
Batch Size in vials from Quotation 

4.2.4
Number of Batches 

4.2.5
Delivery Date (Date for BVL to release the lot and deliver Product & batch record) 

4.2.6
BVL Quotation Number for Product/Service 

4.2.7
Delivery Address 

4.2.8
Shipping requirements & Instructions (temperature, dedicated trucks, preferred carrier, overnight etc.) Contact name for Preferred Carrier, Temperature Monitors, Ship on BVL Release or
Hold for Customer Authorization to Ship or Ship in Quarantine. 

4.2.9
Billing Address 

4.2.10
Special Instructions for Specific Batch 

(Examples)

"Annual Stability Batch"

"Process Validation Batch"

"Special Sampling Instructions" mutually agreed to in advance

4.2.11
Customer Lot# and Expiration Date if Applicable 

5.     Forecast & Planning  

5.1
Customer shall submit at least (CONFIDENTIAL TREATMENT REQUESTED) before the start of each calendar quarter an updated estimate for both volumes and delivery dates of its requirement for Product
for the following (CONFIDENTIAL TREATMENT REQUESTED). The estimated requirements for the (CONFIDENTIAL TREATMENT REQUESTED) of these (CONFIDENTIAL TREATMENT REQUESTED) shall be considered firm orders
for which Customer will issue purchase orders pursuant to Section 4 of this agreement. In addition a (CONFIDENTIAL TREATMENT REQUESTED) forecast will be submitted by the Customer to BVL on an
annual basis due by February 28th each year for the following (CONFIDENTIAL TREATMENT REQUESTED). Ben Venue shall provide Customer with a forecast template to be used for all
forecasts. All forecasts provided shall be non binding on either party, unless agreed to in writing by both parties and shall be subject to acceptance of a purchase order which will be confirmed in
writing by BVL. 

6.     Insurance and Liability Limits  

6.1
Customer will retain title to and risk of loss of the bulk active drug substance, in process and in finished Product, except if BVL damages the material while in storage at BVL's
facility, due to BVL's negligence or willful misconduct. BVL will maintain general liability insurance in an amount sufficient to cover the replacement cost of Customer supplied raw
materials up to (CONFIDENTIAL TREATMENT REQUESTED), and will include Customer as an additional insured under the relevant policies. For Process related losses see BVL 6.2. 

6.2
After such time as all Production and Testing Procedures have been fully developed and validated and a complete and successful technical transfer to BVL's production department has
occurred, BVL will reimburse Customer up to $(CONFIDENTIAL TREATMENT REQUESTED) per batch for any loss of customer supplied raw materials and/or components and will issue a credit for the
manufacturing fee, if an invoice for the manufacturing fee has been issued for the production, for any batch of Product which does not meet the specifications contained in the master batch record, 

pro-rated
over the usable portion of the batch if applicable. The monetary values of all Customer supplied raw materials and components must be disclosed to BVL prior to production in the
questionnaire provided by BVL to Customer. The Customer is responsible for notifying BVL in writing of any changes in the value of the raw material or components supplied to BVL. Further, any such
claim for a loss must be due to failure of BVL's personnel to follow directions or to gross negligence on their part. 

6.3
Neither party will be liable to the other party for consequential damages, including but not limited too loss of sales, profit, clinical trial costs, regardless of the reason for such
consequential damages. 

7.     Safety  

7.1
BVL and Customer shall mutually develop safety procedures for the handling and manufacture of Product and treatment and disposal of waste relating thereto that comply with all federal and state
environmental and occupational safety and health requirements. Such procedures shall be included in a separate document and shall be followed by BVL and Customer in performing services under this
agreement. 

7.2
Customer will provide Material Safety Data Sheets and other handling information required by law, to be provided prior to shipment of any material to BVL. BVL will not receive any material until
all required information has been provided. 

7.3
Customer will provide BVL with all information regarding safety of biological and drug Products and will maintain currency of such information. 

8.     Payment and Pricing  

8.1
Customer acknowledges that all invoices must be paid to BVL no later than (CONFIDENTIAL TREATMENT REQUESTED) days after the date of invoice, payment terms are (CONFIDENTIAL TREATMENT REQUESTED).
For manufacturing services an invoice will be issued after BVL's Documentation Department has issued a Certificate of Compliance or, if applicable, at the time a Quarantine shipment is
made, for non production services invoices will be sent in accordance with the terms outlined in Proposals / Quotations provided to Customer as work is performed for those services. Any invoice(s)
remaining to be paid after (CONFIDENTIAL TREATMENT REQUESTED) days from the date of the invoice(s), unless such invoice(s) are in dispute, will result in BVL requiring Customer to pay all or part of
the fee for services in advance for future orders until such time as Customer has reestablished its credit. In order to avoid penalty, Customer must notify BVL within (CONFIDENTIAL TREATMENT
REQUESTED) after receipt of invoice if invoice is to be disputed. 

8.2
Customer acknowledges that all prices of Product shall be on the basis of (CONFIDENTIAL TREATMENT REQUESTED). 

8.3
Customer may be asked to prepay a minimum of (CONFIDENTIAL TREATMENT REQUESTED) of the amount of the Purchase Order with the Purchase Order, until acceptable credit history is established. 

8.4
BVL will consider that the Product has been accepted by Customer, unless BVL is notified in writing within (CONFIDENTIAL TREATMENT REQUESTED) after shipment of the completed batch record that the
Product fails to conform to applicable specifications. 

8.5
Pricing will be established in Proposal/Quotations provided to Customer by BVL. 

9.     Cancellation or Postponement  

9.1
Customer will pay a cancellation fee of (CONFIDENTIAL TREATMENT REQUESTED) of the price of the quoted batch if cancellation or postponement is within (CONFIDENTIAL TREATMENT REQUESTED) weeks of
the scheduled manufacturing date. If cancellation occurs within 

(CONFIDENTIAL
TREATMENT REQUESTED) weeks of the scheduled fill date, Customer is responsible for paying (CONFIDENTIAL TREATMENT REQUESTED) price of the scheduled production. 

10.   Storage  

10.1
(CONFIDENTIAL TREATMENT REQUESTED) is responsible for storage charges for Products stored more than one month beyond BVL's release. A formal quotation for these charges may be
obtained from (CONFIDENTIAL TREATMENT REQUESTED) Contract Service Department. These charges are reviewed annually. Short term storage of Product in BVL's warehousing facilities beyond
one month must receive prior approval from BVL. Such approval will be granted on a space-available basis. 

11.   Stability Program  

11.1
Customer is responsible for stability testing program. Customer may contract with BVL to perform stability testing under separate proposals provided to Customer by BVL based on a mutually agreed
to protocol. 

12.   Retention Samples  

12.1
Customer is responsible for maintaining retention samples of all finished Product shipped to Customer. 

13.   Release for Sale and/or Distribution  

13.1
Customer is responsible for release of the final Product for sale or distribution. 

14.   Complaints  

14.1
Customer is responsible for maintaining complaint file and notifying BVL of complaints relating to manufacturing defects. 

15.   Regulatory  

15.1
Customer is responsible for securing the necessary regulatory approvals for the Product. 

15.2
Customer is responsible for Drug Listing of Product and providing a copy of Drug Establishment Regulatory Form 2656 to BVL once Product is approved by U.S. FDA for marketing. 

15.3
Customer will certify that the Product to be manufactured by BVL shall not be processed, packed, or distributed in violation of any provision of the Federal Food, Drug and Cosmetic Act. 

15.4
Customer is responsible for all Product specific Agency(s) filings including the Annual Report filing with the FDA. 

15.5
Customer is responsible to insure that all filings with any agency are consistent with the specifications for the Product contained in BVL's Master Batch Record, BVL SOP's or
incorporated by reference in these documents. 

16.   Confidentiality

16.1
The terms of this Confidentiality section are mutual between BVL and Customer as either a Disclosing Party or Receiving Party as the case may be. 

16.2
The Disclosing party will provide to the Receiving party certain information including but not limited to, data, reports, patents, patent applications, trade secrets, or the like concerning any
scientific, technical, financial, trade, or business information applicable to the project, the Confidential Information. The Receiving party agrees to protect and keep confidential all Confidential
Information and all notes of information obtained pursuant to this Agreement. The Receiving Party agrees that it shall limit its use of the Confidential Information to performing certain services as
mutually agreed to in writing by the Parties. The Receiving Party also agrees that it shall not use any Confidential Information, directly or indirectly, for its own benefit or that of any person,
firm or corporation other than the Disclosing Party. All information exchanged regardless of format shall be considered Confidential Information. 

16.3
The Receiving Party agrees and acknowledges that the Confidential Information to be disclosed to it pursuant to this Agreement constitutes unique and valuable commercial and proprietary
information of the Disclosing Party. Accordingly, the Receiving Party shall not duplicate, disclose, or discuss any such Confidential Information to or with third parties, without the prior written
consent of the Disclosing Party. Except that the Receiving Party may disclose Confidential Information received by it under this Agreement only to those of its directors, officers, employees, agents,
and consultants who have a need to know such Confidential Information in the course of the performance of their duties with respect to the purposes of this Agreement and who are bound by written
agreement to protect the confidentiality of such Confidential Information in accordance with the terms hereof. 

16.4
Notwithstanding anything to the contrary herein, the Receiving Party shall not be obligated to maintain the confidentiality of any information provided to it under this Agreement which: 

a.
Is already in the public domain at the time of disclosure to it, or 

b.
at any time after disclosure to the Receiving Party becomes public knowledge through no fault of the Receiving Party; 

c.
is disclosed to the Receiving Party by any third party who is free to make such disclosure; or 

d.
is disclosed by the Receiving Party with the prior written consent of the Disclosing Party, or 

e.
is information which the Receiving Party can establish was in it's possession prior to disclosure or was subsequently and independently developed by employees of or on behalf of the Receiving Party
without use, direct or indirect, of Confidential Information protected by this Agreement. 

f.
is required to be disclosed pursuant to a requirement of law, subject to provisions outlined in Item 16.8 of Section 16 of this agreement. 

16.5
The confidential undertakings and agreements of the Receiving Party shall survive termination of this Agreement. Promptly upon termination of this Agreement and request of the Disclosing Party,
the Receiving Party shall return to the Disclosing Party all notes of information obtained pursuant hereto and summaries thereof and any copies of documents of the Disclosing Party, personnel
interviews, or other Confidential Information in its possession. This agreement shall not be construed as a grant of any right or license to the Receiving Party with respect to Confidential
Information or the Disclosing Party's Product or as a requirement to either party to enter into any further arrangement with respect to Confidential Information or the Disclosing Party's Product. 

16.6
The confidentiality obligations of this agreement shall be maintained for a period of five years beyond the expiration or termination of this Agreement. 

16.7
Provided all obligations of this agreement are maintained, the parties understand and acknowledge that the other may now market or have under development products which are competitive with
products now offered or which may be offered by the other, and the parties' communications hereunder will not serve to impair the right of other to develop, make, use, procure, or market products or
services now or in the future which may be competitive to those offered by the other party nor for the parties to disclose any planning or other information to the other. 

16.8
Notwithstanding any provision herein to the contrary, in the event that any Receiving Party hereafter becomes obligated by mandatory applicable law, regulatory rule or judicial or administrative
order to disclose Confidential Information or any portion thereof, to any third party, governmental authority or court, the Receiving Party shall immediately notify the Disclosing Party thereof of
each such requirement and identify the Confidential Information so required thereby, so that the Disclosing Party may seek an appropriate protective order or other remedy with respect to narrowing the
scope of such requirement and/or waive Receiving Party's compliance with the provisions of this Agreement. 

16.9
Both parties agree that should this Agreement be breached, money damages would be inadequate to remedy such a breach. As a result, the non-breaching party shall be entitled to seek,
and a court of competent jurisdiction may grant, specific performance and injunctive or other equitable relief as a remedy for any such breach of this Agreement. Such remedy shall be in addition to
all other remedies, including money damages, available to a non-breaching party at law or in equity. 

16.10
Upon request, each party shall return all copies of the Confidential Information to the other party, except for a single copy to be kept by it's legal counsel in its confidential file for the
purpose of determining compliance with its obligations of this agreement. 

16.11
Neither party will issue any press release or other public announcement relating to any activities involving the other party without the prior written consent of the other party, except where
such announcements are required by law or regulation. The parties will use all reasonable efforts to consult with the other and cooperate with respect to wording of any such announcement. 

17.   Batch Rejections  

17.1
BVL will reserve the right to sample and retest Product if, prior to Customer's release, Customer claims that Product fails to meet applicable specifications. 

17.2
Customer will provide an approved rework procedure (if Product can be reworked). 

17.3
In the event of a rejection of a batch of Product, BVL will cease further production of Product until such time as the results of the investigation have been communicated to Customer and Customer
has confirmed the corrective action. Should Customer desire to have Product manufactured while the investigation is in process, (CONFIDENTIAL TREATMENT REQUESTED) will be responsible for the fees for
service performed by BVL whether the batch is accepted or rejected by Customer or BVL. (CONFIDENTIAL TREATMENT REQUESTED) will provide a written statement of financial responsibility (CONFIDENTIAL
TREATMENT REQUESTED) (CONFIDENTIAL TREATMENT REQUESTED) while investigations and corrective actions are being determined by BVL and Customer. 

17.4
Customer may reject any commercial, developmental or clinical Products manufactured for Customer if such Products fail to comply with Manufacturing Instructions and Specifications, incorporated
in the master batch record, previously agreed upon by Customer and Ben Venue. However, until such time as all manufacturing processes and/or analytical procedures are validated, (CONFIDENTIAL
TREATMENT REQUESTED) will be financially responsible for all BVL fees for services for each batch of Product provided by BVL, at prices confirmed by quotation(s) and purchase orders, unless such batch
is rejected due to the gross negligence of BVL. Customer acknowledges that until all processes and methods are validated that additional cost may be incurred for unanticipated developmental issues. 

18.   Term and Termination  

18.1
This agreement remains in effect until superceded by a future agreement or upon termination by either party. 

18.2
This agreement may be terminated by (CONFIDENTIAL TREATMENT REQUESTED) by giving (CONFIDENTIAL TREATMENT REQUESTED) written notice to (CONFIDENTIAL TREATMENT REQUESTED). 

19.   Notices  

19.1
All notices required or permitted hereunder shall be given in writing and sent by mailed postage prepaid, certified or registered mail, return receipt requested, or sent by a nationally
recognized express courier service, or hand-delivered at the following addresses: 

	If to Ben Venue:	 	Ben Venue Laboratories, Inc.

A Boehringer-Ingelheim Company

Attn: General Manager

Contract Manufacturing Services

300 Northfield Road

Bedford, Ohio 44146

Fax: 440-439-6398
	

If to COMPANY:	
 	

MedImmune, Inc.

Attn: Senior Director, Supply Chain Management

660 Research Drive

Frederick, MD 21703
	

Cc.	
 	

MedImmune, Inc.

Attn: Legal Affairs

35 West Watkins Mill Road

Gaithersburg, MD 20878

        Notices
shall be effective upon receipt. A party may change its address listed above by written notice to the other party. 

20.   Amendments and Waiver of Provision  

20.1
This Agreement may only be amended by a written instrument duly executed by both parties. 

20.2
No waiver of any provision of this Agreement shall be effective unless the party whose rights are being waived duly executes it. No waiver with respect to any one occurrence, action, or inaction
shall be effective with respect to any subsequent or other occurrence, action or inaction, similar or otherwise. 

21.   Assignment  

21.1
This Agreement may not be assigned by either party hereto EXCEPT to an affiliate or a purchaser of all or substantially all of the stock or assets of either one of the parties without the prior
written consent of the other and shall be binding upon and inure to the benefit of the successors and permitted assigns of each party. 

22.   Governing Law  

22.1
This Agreement and the rights, duties and obligations of the parties hereunder shall be governed by and construed in accordance with the laws of the State of Delaware, USA. 

23.   Miscellaneous  

23.1
Customer will provide the name and phone numbers of a contact person(s) who may be called at any hour during the times when BVL is manufacturing the Product. 

23.2
Nothing contained in this Agreement shall be construed, by implication or otherwise, as an obligation to enter into any further agreement relating to any of the Confidential Information or as the
grant of a license to either party to use the other's Confidential Information other than for the purpose herein. 

        These terms and conditions supersede any conflicting Terms and Conditions contained with the Customer's Purchase Orders or on BVL's Purchase Order
acknowledgment. Customer acknowledges that these terms and conditions are incorporated by reference on every purchase order.

THIS DOCUMENT SUPERSEDES ALL OTHER DOCUMENTS AND AGREEMENTS.  

	For BEN VENUE LABORATORIES, INC. (BVL)	 	 
	

BY	
 	

/s/    Peter Hansbury, R. Ph.

        Peter Hansbury, R. Ph.

        General Manager, Contract Manufacturing Services	
 	

DATE: 10/17/2003
	

For: Customer	
 	

 
	

BY	
 	

/s/    Edward Goley

        Edward Goley

        Vice President and General Manager, Manufacturing	
 	

DATE: 10/16/2003Exhibit 10.26  

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED AS "(CONFIDENTIAL TREATMENT REQUESTED)" IN THE TEXT, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

SECOND AMENDED AND RESTATED

PRODUCTION AGREEMENT

BETWEEN

CARDINAL HEALTH 406, INC.

AND

MEDIMMUNE VACCINES, INC.  

        This Second Amended and Restated Production Agreement (the "Agreement") is made effective as of
December 31, 2003 (the "Effective Date") by and between Cardinal Health 406, Inc., a Pennsylvania corporation with offices at 3001 Red
Lion Road, Philadelphia, Pennsylvania 19114 (hereinafter called "Cardinal Health"); and MedImmune Vaccines, Inc., a Delaware corporation with
offices at 35 West Watkins Mill Road, Gaithersburg, Maryland 20878 (hereinafter called "MedImmune"). Cardinal Health and MedImmune may be referred to
herein as a "Party" or, collectively, as "Parties." 

WITNESSETH  

        WHEREAS, Cardinal Health specializes in packaging for the pharmaceutical industries and has certain technical and
commercial information and know-how relating to, among other things, performing assembly functions and packaging of pharmaceutical products. 

        WHEREAS, MedImmune is a corporation that develops, registers, manufactures and markets pharmaceutical products, and is the owner of
certain proprietary technical and commercial information and know-how relating to, among other things, the formulation and development of such products. 

        WHEREAS, MedImmune desires to engage Cardinal Health to provide certain services to MedImmune in connection with the packaging of certain
of MedImmune's products; 

        WHEREAS, Cardinal Health, formerly known as Packaging Coordinators, Inc., and the predecessor-in-interest
of MedImmune, namely Aviron, a Delaware corporation, previously entered into a Production Agreement, effective as of October 31, 1997, providing for such packaging, and such agreement was
amended and restated effective as of August 1, 2000 (as so amended, the "First Amended and Restated Production Agreement"); and 

        WHEREAS, the parties desire to reallocate the responsibilities for such manufacture between them and to further amend and restate the
First Amended and Restated Production Agreement in its entirety; 

        NOW, THEREFORE, in consideration of the premises and the mutual promises contained herein and intending to be legally bound hereby, the
Parties agree as follows: 

        1.    DEFINITIONS    The following terms as used in this Agreement shall have the meanings set forth in this Article
unless otherwise specifically provided herein: 

        1.1.  "Affiliate(s)" shall mean any corporation, firm, partnership or other entity which controls, is controlled by or is
under common control with a Party. For purposes of this definition, control shall mean the ownership of at least fifty (50%) percent of the voting share capital of such entity or any other comparable
equity or ownership interest. 

        1.2.  "Agency" shall mean any governmental regulatory authority involved in regulating any aspect of the development,
Manufacture, Storage and sale of the Product. 

 

        1.3   "MedImmune Facility" shall mean the portion of the Cardinal Health Facility that is subject to the Facility Reservation
Agreement and which is dedicated to Primary and Secondary Production, or such other facility as my be mutually agreed in writing by the Parties. 

        1.4   "MedImmune Production Equipment" shall mean any Secondary Production equipment purchased by MedImmune for use by Cardinal
Health pursuant to this Agreement. 

        1.5   "cGMP" shall mean all the laws, regulations and standards relating to Secondary Production, including but not limited to,
the United States Food And Drug Administration (FDA) current Good Manufacturing Practices, as set forth in the Code of Federal Regulations (CFR), and the EEC Good Manufacturing Guidelines, Volume IV
as such Regulations and Guidelines may be revised from time to time, and any other applicable laws, guidelines and regulation. If there should be a conflict between the FDA and EEC standards, the more
stringent of the two shall apply. MedImmune shall be responsible to advise Cardinal Health of cGMP and other Agency requirements which shall apply to Secondary Production conducted hereunder. 

        1.6   "Delivery Date" shall mean the date on which Product is delivered from Cardinal Health to MedImmune pursuant to
Section 7.2. 

        1.7   "Facility Reservation Agreement" shall mean that certain agreement dated October 31, 1997, as amended from time to
time, relating to the build-out and use of the MedImmune Facility. 

        1.8   "FDA" shall mean the United States Food and Drug Administration and any successor agency having substantially the same
function. 

        1.9   "Materials" shall mean all components utilized in Secondary Production except for the Primary Product. 

        1.10 "Michigan" shall mean the Regents of the University of Michigan, a constitutional corporation of the State of Michigan
with offices located at Wolverine Tower, Room 2071, 3003 South State Street, Ann Arbor, Michigan, 48109-1280, USA. 

        1.11 "Michigan Agreement" shall mean a certain Materials Transfer and Intellectual Property Agreement between MedImmune and
Michigan dated 24 February 1995. 

        1.12 "Packaging Specifications" shall mean the procedures, Standard Operating Procedures, components specifications, test
results, requirements, quality standards data and other documentation with respect to Materials, Secondary Production, Product Production Equipment and Storage, including, without limitation, those
appended hereto as Appendix 2, as the same may be amended from time to time. 

        1.13 "Cardinal Health Facility" shall mean Cardinal Health's facility at 3001 Red Lion Road, Philadelphia, Pennsylvania, or
such other facility as may be mutually agreed in writing by the Parties. 

        1.14 "Cardinal Health Production Equipment" shall mean all of the packaging, labeling and testing equipment purchased by
Cardinal Health as set forth in Appendix 1, which may be amended from time to time. 

        1.15 "Primary Product" shall mean the product that is the result of Primary Production. 

        1.16 "Primary Production" shall mean the blending and aseptic filling of Vaccine in a syringe. 

        1.17 "Primary Product Specifications" shall mean the procedures, Standard Operation Procedures, test results, requirements,
quality standards data and other documentation developed by MedImmune with respect to Primary Product. 

        1.18 "Product" shall mean the product which is the result of Primary and Secondary Production. 

        1.19 "Proprietary Information" shall have the meaning set forth in Article 12. 

2

 

        1.20 "Secondary Area" shall mean the area at the MedImmune Facility reserved for Secondary Production as designated by
MedImmune in consultation with Cardinal Health. 

        1.21 "Secondary Production" shall mean assembly, labeling and packaging of Primary Product and Storage, in accordance with
the Packaging Specifications. 

        1.22 "Store" or "Storage" shall mean the storage of Product, Materials and/or
Stored Materials, as set forth in the Packaging Specifications. 

        1.23 "Stored Materials" shall mean all Materials, Syringes and other supplies to be used by MedImmune in connection with
Primary Production (other than normal allantoic fluid and vaccine). 

        1.24 "Syringe" shall mean the unfilled sprayer and stopper, as set forth in the Packaging Specifications. 

        1.25 "Vaccine" shall mean the bulk cold-adapted influenza vaccine, as set forth in the Packaging Specifications. 

        2.    REPLACEMENT OF FIRST AMENDED AND RESTATED PRODUCTION AGREEMENT    By entering into this Agreement, the Parties
hereby amend and restate the First Amended and Restated Production Agreement in its entirety. Except for rights and obligations accrued as of the Effective Date, all rights and obligations arising
thereunder are hereby terminated as of the Effective Date. 

        3.    PRODUCTION EQUIPMENT    

        3.1.    Installation and Qualification.    Each Party will, at its sole expense, provide, install in the Secondary
Area, validate and qualify its respective Production Equipment in compliance with cGMP. MedImmune will perform process validation on the packaging line and Cardinal Health will assist MedImmune in the
validation process with its operators and engineers. 

        3.2.    Maintenance.    Cardinal Health agrees to maintain and operate the MedImmune and Cardinal Health Production
Equipment used for Secondary Production, in all material respects, in accordance with (a) cGMPs, (b) applicable Agency requirements and (c) the Packaging Specifications. As to the
MedImmune Production Equipment, Cardinal Health shall be responsible for routine maintenance in accordance with the equipment manufacturers' guidelines, cGMPs and other applicable laws and
regulations, and for other repairs required as a result of the negligence or intentional misconduct of Cardinal Health or its employees. MedImmune shall bear all other expenses incurred for the
maintenance (other than routine maintenance), repair and/or replacement, of the MedImmune Production Equipment. MedImmune shall be responsible for all expenses and maintenance (including routine
maintenance) for any other equipment, used in Primary Production, including, without limitation, the freezer, but not including, in any case, the building equipment required to be maintained by
Cardinal Health pursuant to the Facility Reservation Agreement. For the purpose of this Agreement, routine maintenance shall mean preventive maintenance and calibration, as set forth in the Packaging
Specification. 

        3.3.    Ownership.    MedImmune shall at all times hold all right, title and interest in the MedImmune Production
Equipment. Cardinal Health shall not, at any time during the term of this Agreement, encumber the MedImmune Production Equipment. Cardinal Health shall at all times hold all right, title and interest
in the Cardinal Health Production Equipment. MedImmune shall not, at any time during the term of this Agreement, encumber the Cardinal Health Production Equipment. Upon the other Party's request, each
Party shall provide evidence to the other Party's reasonable satisfaction indicating that Party's Production Equipment is insured and that such insurance covers the other Party (as an additional
insured) for any loss or damage to the other Party, or its property or employees, except where such loss or damage is a result of the negligence or intentional misconduct of the other Party or its
employees. 

3

 

        3.4.    Changes to Equipment.    As it relates to Secondary Production, neither Party may modify, alter or otherwise
use different equipment other than that Party's Production Equipment without the written consent of the other Party. The costs for any approved changes to a Party's Production Equipment, including,
but not limited to, changes requiring validation or other associated costs, will be borne by the Party making the request, except as otherwise agreed upon by the Parties. Validation or
re-validation of Production Equipment after a change under this Section 3.4 will be performed by the owner of the Production Equipment subject to the reasonable approval of the
other Party and such other conditions as the Parties may agree upon before implementing the proposed change. 

        4.    COORDINATION; SUPERVISION WITHIN THE SECONDARY AREA    

        4.1.    MedImmune Technical Representative.    MedImmune shall have the right to have one or more representatives in
the Secondary Area during Secondary Production to (a) review Production Equipment and Secondary Production, (b) review any relevant records in connection with such Secondary Production
and assess its compliance with cGMP and quality assurance standards set forth in the Packaging Specifications and (c) discuss any related issues with Cardinal Health's management. MedImmune's
technical representatives, when in the Secondary Area, shall comply with Cardinal Health's rules and regulations. MedImmune shall indemnify and hold Cardinal Health and its Affiliates harmless from
all liability, including claims by MedImmune's technical representatives for workers' compensation, resulting from the presence of MedImmune's technical representatives at the MedImmune Facility
except for claims resulting from the negligent or willful misconduct on the part of Cardinal Health and its employees or breach by Cardinal Health of its obligations hereunder or under the Facility
Reservation Agreement. 

        4.2.    Responsibilities.    MedImmune's technical representative, if present, shall not have responsibility for the
supervision of Cardinal Health's personnel conducting Secondary Production. However, if at any time MedImmune's technical representatives feel that Cardinal Health is operating in a manner
inconsistent with this Agreement, he/she is to notify Cardinal Health immediately to cease operations until such condition is remedied. Cardinal Health will immediately cease operations and will not
recommence Secondary Production operations without MedImmune's approval. Cardinal Health shall use its best efforts to remedy any such condition and MedImmune shall authorize Cardinal Health to resume
Secondary Production upon reasonable satisfaction that such condition has been remedied. Nothing herein shall amend or alter the status of Cardinal Health as an independent contractor. 

        4.3.    Coordination of Primary and Secondary Production.    MedImmune and Cardinal Health shall mutually agree in
writing upon and arrange for each of the following activities and any additional activities that are necessary or useful to permit MedImmune to undertake Primary Production at the MedImmune Facility
or to permit the Parties to coordinate Primary Production with Secondary Production: 

        (a)   Provision
for the delivery of materials and equipment for Primary Production; 

        (b)   Transfer
of Primary Product at designated times from MedImmune to Cardinal Health in a manner that ensures Storage in compliance with the Packaging Specifications at all
times; 

        (c)   Delivery
of Product pursuant to Section 7.2 in a manner that ensures Storage in accordance with the Packaging Specifications; 

        (d)   Communication
as to other issues arising from MedImmune's conduct of Primary Production, Cardinal Health's conduct of Secondary Production, other activities of Cardinal
Health at the MedImmune Facility pursuant to the Facility Reservation Agreement, or coordination of Primary and Secondary Production; and 

        (e)   Designation
of a representative of each party to coordinate and facilitate the activities of (a) to (d). 

4

 

        5.    FORECAST, PURCHASE AND SUPPLY OF PRODUCT    

        5.1.    Secondary Production.    During the term of this Agreement, Cardinal Health shall perform Secondary Production
of such quantities of Product as may be set forth on orders placed by MedImmune under this Agreement. All Secondary Production and deliveries of Product hereunder shall be governed by the terms of
this Agreement which shall supersede any inconsistent provisions in any order delivered by MedImmune to Cardinal Health. 

        5.2.    Forecasts.    On or before (CONFIDENTIAL TREATMENT REQUESTED) of each year during the term of this Agreement,
MedImmune will provide Cardinal Health with a written (CONFIDENTIAL TREATMENT REQUESTED) forecast, to be updated in (CONFIDENTIAL TREATMENT REQUESTED) intervals, of the quantity of Product which
MedImmune expects to require form Cardinal Health during each of the next (CONFIDENTIAL TREATMENT REQUESTED). The first (CONFIDENTIAL TREATMENT REQUESTED) of the first such rolling forecast shall be
binding upon MedImmune, subject to the provisions of Section 5.6 below. MedImmune's first forecast shall include (a) the required Delivery Date for the binding portion of the forecast
and (b) the quantity of Product to be delivered. 

        5.3.    Orders.    According to the forecast, MedImmune will provide Cardinal Health with one or more orders at
(CONFIDENTIAL TREATMENT REQUESTED) intervals. Each such order will set forth (a) the quantity of Product ordered for delivery during the (CONFIDENTIAL TREATMENT REQUESTED) after the date on
which the order is deemed to be received, (b) the requested Delivery Date for such order, (c) the quantity of Product to be delivered to MedImmune as a quality control sample and
(d) the quantity of Product to be delivered on the Delivery Date in each form of packaging. Such order shall be delivered no later than (CONFIDENTIAL TREATMENT REQUESTED) days prior to the
earliest requested Delivery Date. 

        5.4.    Confirmation; Orders Greater than Forecast.    Within fifteen (15) days of receipt of any order,
Cardinal Health shall confirm in writing such order and the Delivery Date therefore. Cardinal Health shall use reasonable commercial efforts to supply the quantity of Product ordered, regardless of
the quantity forecast by MedImmune, subject to the capacity limitations of the MedImmune and Cardinal Health Production Equipment and to the ability of MedImmune to supply Primary Product to Cardinal
Health pursuant to Section 6.2. In the event that Cardinal Health is unable to fill any order, Cardinal Health shall so notify MedImmune in its written confirmation. 

        5.5.    Amendment of Orders.    Cardinal Health will use best efforts to accommodate a request to amend an order to
increase or decrease the quantity of Product to be delivered. 

        5.6.    Cancellations.    MedImmune may cancel any order by providing Cardinal Health written notice at any time prior
to the confirmed Delivery Date. In the event that MedImmune cancels any order for Product, MedImmune shall pay Cardinal Health at the rates set forth in Section 13.1 for (CONFIDENTIAL TREATMENT
REQUESTED) Cardinal Health in connection with performance of such order up to the time of receipt of such notice, including, without limitation, (CONFIDENTIAL TREATMENT REQUESTED) prior to the
confirmed Delivery Date, based upon MedImmune's binding forecast (as set forth in Section 5.2 above). 

        5.7.    Supply Commitments.    Subject to the limitations set forth in Section 5.4, Cardinal Health represents
and warrants that it has the ability to, and hereby covenants that it will, supply the quantity of Product ordered by MedImmune. 

        5.8.    Limited Warranty.    CARDINAL HEALTH WARRANTS THAT PRODUCT DELIVERED HEREUNDER WILL (a) BE PACKAGED BY
CARDINAL HEALTH IN ACCORDANCE WITH cGMP AND OTHER APPLICABLE FEDERAL, STATE AND LOCAL LAWS AND REGULATIONS, INCLUDING BUT NOT LIMITED TO FDA REGULATIONS, (b) BE PACKAGED IN ACCORDANCE WITH THE
PACKAGING SPECIFICATIONS AND 

5

 

(c) CONFORM
AS OF THE DELIVERY DATE TO THE APPLICABLE PACKAGING SPECIFICATIONS, AS THEN IN EFFECT, SUBJECT TO NONCONFORMITIES IN PRIMARY PRODUCT EXISTING AT THE TIME OF DELIVERY TO CARDINAL
HEALTH. EXCEPT AS SET FORTH HEREIN, CARDINAL HEALTH MAKES NO WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE PRODUCTS, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE. 

        6.    SUPPLY AND PROCESSING OF PRIMARY PRODUCT, SYRINGES AND MATERIALS    

        6.1.    License; Inventions.    

        (a)   MedImmune
hereby grants to Cardinal Health, during the term of this Agreement, a non-exclusive, non-transferable, royalty-free
license during the term of this Agreement to use the data, information and technology provided by MedImmune related to the Vaccine and the Primary Product for the limited purpose of assisting Cardinal
Health in carrying out its obligations set forth in this Agreement. 

        (b)   Cardinal
Health agrees that any and all idea, improvements, inventions and works of authorship conceived, written or first reduced to practice whether by Cardinal
Health's employees alone or in conjunction with MedImmune, if any, that are related to the Vaccine or Primary Production (the "MedImmune Inventions")
shall be the sole and exclusive property of MedImmune and Cardinal Health hereby assigns to MedImmune all right, title and interest in and to any and all such MedImmune Inventions. 

        (c)   MedImmune
agrees that any and all ideas, improvements, inventions and works of authorship conceived, written or first reduced to practice in the performance of this
Agreement that are related to Secondary Production (the "Cardinal Health Inventions") shall be the sole and exclusive property of Cardinal Health and
MedImmune assigns all right, title and interest in and to any and all such Cardinal Health Inventions. Cardinal Health hereby grants to MedImmune a non-exclusive, worldwide,
royalty-free license to use and practice such Cardinal Health Inventions for the manufacture, by or for MedImmune of any of MedImmune's products. Such license shall survive the termination
or expiration of this Agreement. 

        6.2.    Supply of Primary Product.    MedImmune shall, at MedImmune's expense, on a timely basis, deliver or cause to
be delivered to the Secondary Area or made available at the MedImmune Facility, sufficient quantities of Primary Product meeting the Primary Product Specifications such that Cardinal Health can fill
orders for the Product submitted pursuant to Section 5.3. 

        6.3.    Risk of Loss of Primary Product.    

        (a)   Subject
to the limitations set forth in Section 6.3(c) and Section 9.2(a), Cardinal Health will bear risk of loss for Primary Product delivered or made
available to Cardinal Health under Section 6.2 and for Stored Materials, which loss results from Cardinal Health's failure to comply with the Packaging Specifications or from the negligence or
intentional misconduct of Cardinal Health or its employees. Cardinal Health shall issue MedImmune a credit for such losses for which Cardinal Health bears the risk of loss as described in the
preceding sentence. This credit will be applied against any amounts owed Cardinal Health by MedImmune at the time the credit is issued and to the extent the credit exceeds the amount due, the
remaining portion of the credit will be carried over and applied to the next payments due to Cardinal Health from MedImmune under this Agreement until all such credits (or remainders) are exhausted.
If the Agreement terminates or expires and there is a credit remaining, Cardinal Health shall apply such credit against any sums owed Cardinal Health by MedImmune, and, to the extent there is a credit
balance remaining, shall pay MedImmune the difference. 

6

 

        (b)   Subject
to the limitations set forth in Section 6.3(c) and Section 9.2(a), Cardinal Health will also bear the risk of loss for normal manufacturing losses
of commercial Primary Product containing active ingredients (i.e. excluding media fills) ("Commercial Primary Product") from the entire packaging line
as it exists on June 1, 2003, in excess of (CONFIDENTIAL TREATMENT REQUESTED) of all Commercial Primary Product delivered or made available to Cardinal Health by MedImmune during any Production
Year (as defined in Article 13). Losses shall not include inspection booth rejects, quality assurance testing and challenges and retained samples. If equipment is added to or removed from the
packaging line, the Parties shall negotiate a new normal manufacturing loss percentage. Losses shall be calculated promptly following the conclusion of the Production Year. At the conclusion of each
Production Year, Losses will be reviewed and the allowable loss percentage adjusted accordingly. Cardinal Health shall issue MedImmune a credit for such losses for which Cardinal Health bears the risk
of loss as described in the preceding sentences. This credit will be applied against any amounts owed Cardinal Health by MedImmune at the time the credit is issued and to the extent the credit exceeds
the amount due, the remaining portion of the credit will be carried over and applied to the next payments due to Cardinal Health from MedImmune under this Agreement until all such credits (or
remainders) are exhausted. If the Agreement terminates or expires and there is a credit remaining, Cardinal Health shall apply such credit against any sums owed Cardinal Health by MedImmune, and, to
the extent there is a credit balance remaining, shall pay MedImmune the difference. The parties shall work together to reduce manufacturing Losses. 

        (c)   Cardinal
Health's liability for Primary Product losses under this Agreement, including without limitation under Section 6.3(a), Section 6.3(b) and
Section 7.5 will not exceed (CONFIDENTIAL TREATMENT REQUESTED) For lots equal to or exceeding (CONFIDENTIAL TREATMENT REQUESTED), the cap on Cardinal Health's liability for Primary Product
losses set forth in the preceding sentence will be $(CONFIDENTIAL TREATMENT REQUESTED). For less than full lot quantities, those respective caps will be pro-rated. MedImmune will bear all
risk of loss and responsibility to insure for losses of the Primary Product other than as such risk is specifically assumed by Cardinal Health under this Agreement and above loss limit set forth
herein. 

        (d)   The
Parties agree to work together on process improvements to improve production efficiency and reduce packaging waste. 

        6.4.    Supply of Materials and Inventories.    Cardinal Health shall purchase all Materials, including but not
limited to those set forth in the Packaging Specifications, required to complete the Secondary Production of the Product. Cardinal Health shall provide MedImmune with any inventory of all stored
Materials and Product on a regular schedule, and shall develop computer systems to enable MedImmune to track and monitor inventories, all as required by MedImmune. Detailed inventory transaction
reports will be provided to MedImmune by Cardinal Health on a schedule to be agreed upon by the parties. In the event MedImmune desires to obtain the Materials (other than the cartons, inserts or
lids) from sources other than Cardinal Health, it shall have the right to do so, at its own expense, provided MedImmune notifies Cardinal Health at least ninety (90) days in advance. In the
event MedImmune is able to obtain cartons, inserts or lids (in accordance with the Packaging Specifications) at a cost less than the prices then in effect from Cardinal Health, MedImmune shall notify
Cardinal Health and Cardinal Health shall have an opportunity to agree to match such lower prices. In the event Cardinal Health does not agree to such lower prices, MedImmune shall be permitted to
obtain such Materials from sources other than Cardinal Health, provided MedImmune notifies Cardinal Health at least ninety (90) days in advance. In the event MedImmune purchases such Materials
itself, the price for Product shall be adjusted as set forth in Section 13. 

        6.5.    Labels and Secondary Production.    

        (a)   Thirty
(30) days prior to the intended date of commencement of commercial production, MedImmune shall provide Cardinal Health with: (i) any particular
Packaging Specifications it may have 

7

 

with
respect to labels and packaging materials and (ii) camera-ready artwork for reproduction on labels, package inserts and packaging materials. Such information shall include, but need not be
limited to, the quality, weight and color of the packaging materials and labels, the type and colors of ink to be used in printing for the labels or packaging materials and any special requirements
for the labels or packaging for the Product to be delivered to specific countries. The method to assign lot numbers will be set forth in the Packaging Specifications. 

        (b)   Cardinal
Health shall reproduce the artwork on the labels, packages inserts and packaging materials and imprint the appropriate lot number on each individual unit and
each carton of Product in accordance with the designated lot numbers. Cardinal Health shall conduct all Secondary Production in accordance with the Packaging Specifications. 

        (c)   In
the event that MedImmune desires to change any label, packaging insert or packaging Material for all or any portion of the Product, MedImmune shall supply Cardinal
Health with new camera-ready artwork and work with Cardinal Health to promptly coordinate the use of such new artwork into Secondary Production process. In such event, MedImmune shall purchase from
Cardinal Health, at a price equal to Cardinal Health's cost, all Materials in Cardinal Health's inventory made obsolete by such changes. 

        6.6.    Secondary Production of Product.    

        (a)   Cardinal
Health shall conduct Secondary Production in accordance with the Packaging Specifications and applicable federal, state and local laws and regulations
including, without limitation, cGMP. Cardinal Health shall notify MedImmune of any difficulty in meeting Packaging Specifications or any deviation therefrom immediately upon discovery of such
difficulty. Cardinal Health shall not conduct Secondary Production nor Store Stored Materials or Product at any other location other than the MedImmune Facility without the prior written approval of
MedImmune, and shall keep all Product within the Secondary Area. Before, during and after Secondary Production of each batch of Product, Cardinal Health shall monitor the Secondary Production and
Storage environments (other than the freezers) and keep such records as all of the foregoing are required by the Packaging Specifications and cGMP. Each Party shall promptly notify the other of any
new instructions or specifications required by the FDA or the United States Federal Food, Drug and Cosmetic Act, and of other applicable rules and regulations, and shall confer with each other with
respect to the best means to comply with such requirements and shall allocate any costs of implementing such changes on an equitable basis. 

        (b)   The
Parties agree that it is their intention to identify ways in which to enhance efficiencies in the Secondary Production and so reduce production costs
("Cost Reduction Measures"). In the event Cardinal Health expends amounts in undertaking Cost Reduction Measures, including, for
example, the purchasing of additional production equipment and provided such costs are agreed upon in advance by the parties in writing, MedImmune shall reimburse Cardinal Health for such amounts. Any
additional equipment paid for by MedImmune under this Section 6.6(b) shall be deemed MedImmune Production Equipment. 

        6.7.    Product Specifications; Testing.    

        (a)   Certain
of the Packaging Specifications are appended to this Agreement as Appendix 2. The Parties acknowledge that
those Packaging Specifications set forth in Appendix 2 which are specific to the Secondary Production under this Agreement, namely those
procedures 211.MedImmune.1 through 211.MedImmune.12 and V0008 and V0014, may need to be refined and modified as the Parties gain experience with Secondary Production, testing and use of Product.
Accordingly, the Parties agree to negotiate in good faith to modify those MedImmune specific procedures from time to time as the Parties' experience
with Secondary Production, testing and use of Product warrant; and Cardinal Health further agrees that it will facilitate changes to Appendix 2
that are necessary or appropriate in light of FDA or 

8

 

other
regulatory requirements. The Parties agree to allocate on an equitable basis any special costs of developing and implementing revised procedures. 

        (b)   Product
supplied hereunder will conform to the Packaging Specifications, and such conformance will be verified in accordance with the testing standards and procedures
specified therein. Cardinal Health will forward a sample of each batch of Product to MedImmune for testing and will supply MedImmune with a certificate of release ("Certificate
of Release") confirming that such Product produced meets the Packaging Specifications. 

        (c)   The
Parties agree to work together in good faith to develop more efficient packaging and testing procedures. 

        6.8.    FDA and Regulatory Support.    

        (a)   Cardinal
Health agrees to provide MedImmune with letters of access to any files and documents required by the FDA or regarding Secondary Production. MedImmune shall have
sole responsibility for obtaining from any Agency all permits and/or licenses necessary or required for the sale, marketing or commercialization of Product. MedImmune shall be responsible for all
other filings necessary for approval and import of Product into countries outside the United States. Cardinal Health further agrees to use reasonable commercial efforts to assist MedImmune in
obtaining any government or Agency approval that may be required for the marketing of Product in any country. MedImmune shall provide Cardinal Health with written notice of any additional regulatory
requirements of countries other than the United States that relate to Secondary Production. Cardinal Health shall use its reasonable commercial efforts to comply with such additional requirements and
shall provide MedImmune with prompt written notice of whether it is able to do so. Cardinal Health will provide MedImmune copies of all supporting documentation in Cardinal Health's possession
required for FDA licensing of the Product. MedImmune will hold the FDA and any other Agency license(s) for the Product. 

        (b)   Upon
request, Cardinal Health shall allow access to the MedImmune Facility and inspection of the Secondary Area by FDA or other Agency officials. In the event that the
Secondary Area is audited or inspected by an Agency, Cardinal Health will notify MedImmune immediately by telephone and will provide MedImmune with prompt written notice of such audit. MedImmune will
have, at its option, the opportunity to observe the audit for inspection, and to jointly cooperate with Cardinal Health in any response. Cardinal Health will also promptly provide MedImmune with
copies of any correspondence or reports relating to such audit or inspection. 

        6.9.    cGMP Compliance and QA Audits.    Within ten days of MedImmune's written request, Cardinal Health shall supply
MedImmune with copies of Cardinal Health's manufacturing records, including its batch records, for the purposes of assuring product quality and compliance with the Packaging Specifications. Any found
discrepancies, other than discrepancies resulting from directions received from MedImmune or its representatives, will be reported to Cardinal Health and Cardinal Health will within thirty
(30) days correct said discrepancies to MedImmune's reasonable satisfaction. Failure to do so will give MedImmune the right to terminate this Agreement pursuant to Section 10.5.
MedImmune's failure to exercise its right to audit the Cardinal Health Facility will not represent a waiver of any future exercise of this right or of any other rights under this Agreement, nor does
it represent acceptance of any conditions past or present that might exist or result from such conditions at the Cardinal Health Facility. MedImmune acknowledges that all copies of Cardinal Health's
manufacturing records shall be subject to the confidentiality provisions of Article 12. 

        6.10.    Compliance with Laws.    Cardinal Health shall comply with all applicable present and future orders,
regulations, requirements and laws of any and all applicable, federal, state, and local authorities and Agencies, including without limitation all laws and regulations of applicable to the
transportation, storage, use, handling and disposal of hazardous materials. Cardinal Health represents and warrants to 

9

 

MedImmune
that it has and will maintain during the term of this Agreement all government permits, including without limitation health, safety and environmental permits, necessary for the conduct of
the actions and procedures that it undertakes pursuant to the Agreement. 

        6.11.    Documentation.    Cardinal Health shall keep, for a period of seven years, complete, accurate and authentic
accounts, notes, data and records of the work performed under this Agreement, including those pertaining to the methods and MedImmune Facility used for Secondary Production, testing, and distribution
of Product in accordance with the Packaging Specifications, cGMP, Michigan Agreement and other applicable laws and regulations, and shall promptly provide any such information to MedImmune upon
reasonable request at MedImmune's expense. 

        6.12.    Rework.    Cardinal Health shall not rework any batch of Product without MedImmune's prior written consent,
which consent shall not be unreasonably withheld. 

        6.13.    Samples.    Cardinal Health shall retain quantities of samples of packaging and labeling materials in
accordance with cGMP. Within ten (10) days following MedImmune's written request, Cardinal Health shall provide MedImmune, at MedImmune's expense, with up to one-half the original
amount of the retained samples. 

        6.14.    Storage and Handling.    Cardinal Health shall Store and handle Stored Materials and Product as required by
the Packaging Specifications. 

        6.15.    Corrective Action.    In the event any Agency shall request or order, or if MedImmune shall determine to
undertake, any corrective action with respect to Products supplied hereunder, including any Product recall, customer notice, restriction, change, corrective action or market action, and the cause or
basis for such corrective action results from the material breach by Cardinal Health of Section 5.8, then Cardinal Health shall replace and reship only the lot(s) of Products which are subject
to such corrective action. Cardinal Health shall pay all costs incurred in replacing such Product, including the Primary Product, Materials and shipping costs, subject to the limitations set forth in
Section 9.2. Any costs resulting from corrective actions for any other cause, including but not limited to the Packaging Specifications or Product tampering after the Products have been Shipped
from Cardinal Health's Facility, shall be the sole responsibility of MedImmune. MedImmune shall promptly notify Cardinal Health in writing upon the occurrence of any such corrective action (or, to the
extent practicable, not less than ten days prior thereto). 

        7.    DELIVERY AND ACCEPTANCE OF FINISHED PRODUCT    

        7.1.    Quality Control Sample of Product.    Prior to the delivery of any batch of Product, Cardinal Health shall
deliver to MedImmune (a) a quality control sample of such batch for the purpose of confirming that such batch meets the Packaging Specifications, (b) a copy of the batch records for
such batch, together with written confirmation that such batch records have been reviewed and approved by Cardinal Health's Quality assurance unit and (c) a Certificate of Release. The quality
control sample shall consist of the number of individual Product units specified in the Packaging Specifications. No delivery of Product shall be deemed to have been made until MedImmune accepts or is
deemed to have accepted the quality-control sample and associated documentation in accordance with the Packaging Specifications and Section 7.3. 

        7.2.    Delivery of Product.    All deliveries shall be shipped F.O.B. the Secondary Area, unless otherwise agreed
upon by Cardinal Health and MedImmune in a particular order. (CONFIDENTIAL TREATMENT REQUESTED) shall be responsible for all freight and delivery charges and shall assume all risk of loss of the
Product after transfer of possession to the carrier. 

10

 

        7.3.    Acceptance and Rejection of Product.    

        (a)   MedImmune
may reject any quality control sample or batch delivery which does not conform with the Packaging Specifications or with applicable documentation or other
requirements. Any such notice of rejection shall be in writing and shall indicate the reasons for such rejection. 

        (b)   In
order to reject or put on hold delivery of Product based on testing of a quality control sample, MedImmune must give written notice to Cardinal Health of MedImmune's
rejection of any delivery (i) within (CONFIDENTIAL TREATMENT REQUESTED) following receipt of notification of lot rejection by the FDA, or (ii) within (CONFIDENTIAL TREATMENT REQUESTED)
after receipt of the applicable quality control sample, whichever is later (the "Acceptance Period"). If no such notice of rejection/hold is received during such time period, MedImmune shall be deemed
to have accepted such quality control sample upon the expiration of the Acceptance Period, and Cardinal Health shall be authorized to make delivery of the Product. 

        (c)   After
notice of rejection/hold is given, MedImmune shall cooperate with Cardinal Health in determining whether rejection is necessary or justified and, in situations in
which the type of damage so warrants, provide Cardinal Health with the allegedly non-conforming Product for Cardinal Health evaluation. Cardinal Health will evaluate the cause for such
non-compliance. Cardinal Health shall notify MedImmune as promptly as reasonably possible whether it accepts MedImmune's basis for any rejection. If Cardinal Health disagrees with
MedImmune's determination that certain Product does not meet the Packaging Specifications, such Product shall be submitted to a mutually acceptable third party laboratory. Such third party laboratory
shall determine whether such Product meets the Packaging Specifications and the Parties agree that such laboratory's determination shall be final and determinative. The Party against whom the third
party tester rules shall bear all costs of the third party testing. Whether or not Cardinal Health accepts MedImmune's basis for rejection, promptly on receipt of a notice of rejection/hold of
Product, Cardinal Health shall use reasonable commercial efforts at MedImmune's request to replace such rejected Product. Until such time as the third party tester makes a ruling regarding whether the
Product meets Packaging Specifications, MedImmune shall bear the expenses of such replacement. If the third party tester rules that the Product meets the Packaging Specifications, MedImmune guarantees
to purchase that Product and any replacement Product which Cardinal Health has delivered to MedImmune at the price set forth in Section 13.1. In the event the third party tester rules the
Product does not meet Packaging Specifications, the provisions of Sections 7.4 and 7.5 shall apply. 

        7.4.    Destruction of Product.    Neither Party may destroy any Product alleged not to meet Packaging Specifications
until the third party tester determines whether the Product meets Packaging Specification. Thereafter, upon MedImmune's written request, Cardinal Health shall return to MedImmune or promptly destroy
any rejected Product. The Party determined by the third party tester to be responsible for the failure of such Product to meet the Packaging Specifications shall bear all costs for such return or
destruction. In the event Cardinal Health destroys such Product, Cardinal Health shall provide MedImmune with certification of such destruction. 

        7.5.    Replacement Product.    In the event that Cardinal Health bears responsibility for the failure of Product,
promptly following the rejection of any Product, MedImmune shall deliver sufficient quantities of Primary Product to the MedImmune Facility in order for Cardinal Health to comply with
Section 7.3(c) provided that the production and delivery of such additional Primary Product is reasonably feasible, and can reasonably result in the delivery of completed final Product by
Cardinal Health in sufficient time for market distribution. All direct costs incurred by MedImmune in connection with acquiring, producing and delivering such quantities of Primary Product shall be
the sole responsibility of Cardinal Health, subject to the limitations set forth in Section 6.3(c) and Section 9.2. In accordance with the terms of Sections 6.6 and 6.7, Cardinal Health
shall perform 

11

 

Secondary
Production to deliver to MedImmune the amount of Product originally ordered for the rejected delivery and shall do so as promptly as technically feasible. 

        8.    REPRESENTATIONS AND WARRANTIES    

        8.1.    Existence and Power.    Each Party hereby represents and warrants to the other Party that such Party
(a) is duly organized, validly existing and in good standing under the laws of the state in which it is organized, (b) has the power and authority and the legal right to own and operate
its property and assets, and to carry on its business as it is now being conducted, and (c) is in compliance with all requirements of applicable law, except to the extent that any noncompliance
would not materially adversely affect such party's ability to perform its obligations under the Agreement. 

12

   
        8.2.    Authorization and Enforcement of Obligations.    Each Party hereby represents and warrants to the other
Party
that such Party (a) has the power and authority and the legal right to enter into the Agreement and to perform its obligations hereunder and thereunder and (b) has taken all necessary
action on its part to authorize the execution and delivery of the Agreement and the performance of its obligations hereunder. The Agreement has been duly executed and delivered on behalf of such
Party, and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms. 

        8.3.    No Consents.    Each Party herby represents and warrants to the other Party that all necessary consents,
approvals and authorizations of all Agencies and other persons required to be obtained by such Party in connection with the Agreement have been obtained. 

        8.4.    No Conflict.    Each Party herby represents and warrants to the other Party that the execution and delivery of
the Agreement and the performance of such party's obligations hereunder and thereunder (a) does not conflict with or violate any requirement of applicable laws or regulations or any material
contractual obligation of such Party and (b) does not materially conflict with, or constitute a material default or require any consent under, any material contractual obligation of such Party. 

        8.5.    Non-Debarment.    Cardinal Health represents and warrants that Cardinal Health is not and does
not, to the best of its knowledge, use in any capacity the services of any person barred by an applicable Agency (including, but not limited to, the FDA) from providing such services. Cardinal Health
covenants it will not in the performance of its obligations hereunder use in any capacity the services of any person that it knows is barred by an applicable Agency and will, as soon as practicable
but in no case more than five (5) days after becoming aware of such restriction, disclose in writing to MedImmune that any person who is performing services hereunder is so barred or that any
action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of Cardinal Health's knowledge, threatened, by any applicable Agency relating to the debarment of
Cardinal Health or any person performing services hereunder. 

        9.    INDEMNIFICATION    

        9.1.    Indemnity.    

        (a)   Except
to the extent that claims, suits, losses, damages, costs, fees or expenses arise or result from any negligent or wrongful act or omission of Cardinal Health or
Cardinal Health's breach of Section 5.8, Article 8, or Article 16, MedImmune agrees to indemnify, hold harmless and defend Cardinal Health, its affiliates and their respective
directors, officers, employees and agents, and the directors, officers, employees and agents of any Cardinal Health parent, subsidiary or related company (the "Cardinal Health
Indemnitees") from and against any and all claims, suits, losses, damages, costs, fees and expenses resulting from or arising out of Primary Production, the development,
creation, sale, distribution, possession or use of Product by any person, or asserted by or on behalf of Michigan against the Cardinal Health Indemnitees, including without limiting the generality of
the foregoing any damages, losses or liabilities whatsoever with respect to death or injury to person or damage to property. 

        (b)   To
the extent that such claims, suits, losses, damages, costs, fees or expenses arise or result from any negligent or wrongful act or omission of Cardinal Health or the
breach by Cardinal Health of Section 5.8, Article 8 or Article 16, Cardinal Health agrees to indemnify, hold harmless and defend MedImmune and MedImmune's directors, officers,
employees and agents, and the directors, officers, employees and agents of any MedImmune parent, subsidiary or related company (the "MedImmune
Indemnitees") from and against any and all claims, suits, losses, damages, costs, fees and expenses resulting from or arising out of its Secondary Production, its
transportation, storage, use, handling and disposal of hazardous materials related to such Secondary Production, including without limiting the 

13

 

generality
of the foregoing any damages, losses or liabilities whatsoever with respect to death or injury to person or damage to property. 

        9.2.    Limitation of Liability.    

        (a)   Notwithstanding
anything to the contrary in this Agreement, Cardinal Health's liability (individually or in the aggregate) under this Agreement or in any manner arising
out of this Agreement or its Secondary Production, Storage, use or handling of the Product shall be limited as set forth in this Section 9.2(a) and Section 9.2(b). Cardinal Health's
liability shall not exceed the lesser of (i) (CONFIDENTIAL TREATMENT REQUESTED); and (ii) (CONFIDENTIAL TREATMENT REQUESTED) 

        (b)   IN
NO EVENT SHALL EITHER MEDIMMUNE OR CARDINAL HEALTH BE LIABLE TO THE OTHER FOR ANY SPECIAL, INDIRECT OR CONSEQUENTIAL LOSS, DAMAGE, COSTS OR EXPENSES OF ANY NATURE
WHATSOEVER, INCLUDING, WITHOUT LIMITATION, LOST REVENUES OR PROFITS. 

        9.3.    Notice and Payment.    

        (a)   Promptly
after acquiring knowledge of any damage, loss, deficiency, liability, encumbrances, penalty, cost, expense, action, suit, investigation, proceeding, assessment,
audit, judgment, or claim against which MedImmune or Cardinal Health must indemnify the other pursuant to Section 9.1 (the "Indemnifying Party"),
the Indemnified Party shall give to the Indemnifying Party written notice thereof, specifying the nature of the claim for indemnity (the "Claim
Notice"); provided, however, that the delay or failure to give a Claim Notice shall not be a bar to indemnification hereunder, except and to the extent that the indemnifying
Party is materially prejudiced by the delay or failure to give such Claim Notice. 

        (b)   With
respect to any claim, action, suit, investigation, proceedings, demand, assessment or audit brought by a Third Party ("Third Party
Matter"), the Indemnifying Party shall have the right, at its own expense, to contest and defend against or attempt to settle or compromise (subject to the limitations set
forth below), such Third Party Matter and any damages, losses, deficiencies, liabilities, encumbrances, penalties, costs, expenses and assessments
("Damages") resulting therefrom. If the Indemnifying Party so elects, such defense shall be instituted promptly and the Indemnifying Party shall receive
from the Indemnified Party all necessary and reasonable cooperation in said defense. If the Indemnifying Party is successful in respect of any counterclaim asserted by it in defending a Third Party
Matter, any sums recovered shall first be applied to reimburse the Indemnifying Party for its reasonable out-of-pocket expenses in connection therewith, and any sums in excess
of such amount shall be paid to the Indemnified Party. 

        (c)   In
the event that an Indemnifying Party, after written notice from the Indemnified Party, elects not to defend the same or fails to so notify the Indemnified Party
within thirty (30) days of the giving of the Claim Notice, the Indemnifying Party shall be deemed to have elected not to defend and if the Indemnified Party elects to contest and defend against
such claim, it shall have the right to do so with counsel of its own choosing, at the cost and expense of the Indemnifying Party. 

        (d)   Neither
the Indemnified Party nor the Indemnifying Party shall have the right to settle, compromise or make payment with respect to any claim, demand, or litigation
without the written consent of the other Party, except that the Indemnified Party shall have the right to settle, compromise or make payment with respect to any claim, demand, or litigation against it
without such consent if it has given a Claim Notice to the Indemnifying Party, and (i) the Indemnifying Party has elected, or shall be deemed to have elected, not to defend the same or
(ii) the Indemnifying Party fails to promptly attempt to settle or compromise the claim. 

14

 

        9.4.    Cardinal Health Insurance.    Throughout the term of this Agreement and for policies written on a claims made
basis for five (5) years thereafter, Cardinal Health shall maintain the following minimum insurance coverage with insurance carriers reasonably acceptable to MedImmune: 

        (a)   Commercial
General Liability with per occurrence and general aggregate limits of not less than (CONFIDENTIAL TREATMENT REQUESTED) which shall name MedImmune as an
additional insured and Cardinal Health shall provide a certificate which shall state that Cardinal Health's insurer will endeavor to provide thirty (30) days written notice of any cancellation
prior to the policy expiration date; and 

        (b)   Worker's
Compensation Insurance for Cardinal Health's employees to the full extent required by applicable state law. Cardinal Health will promptly provide MedImmune with
documentation reasonably requested by MedImmune to verify evidence of such insurance coverage. 

        (c)   In
lieu of insurance, Cardinal Health may self-insure any or a portion of the above required insurance. 

        9.5.    MedImmune Insurance.    MedImmune shall purchase and maintain, during the term of this Agreement and for a
period of five (5) years thereafter, at its own cost, product liability insurance with per occurrence and general aggregate limits of not less than (CONFIDENTIAL TREATMENT REQUESTED) and
worker's compensation insurance coverage for MedImmune's employees in amounts required pursuant to applicable state laws, from an insurer reasonably acceptable to Cardinal Health to cover liabilities
which may arise under this Agreement, which insurance shall name Cardinal Health as an additional insured and MedImmune shall provide a certificate which shall state that MedImmune's insurer shall
endeavor to provide thirty (30) days written notice of any cancellation prior to the policy expiration date. In lieu of insurance, MedImmune may self-insure any or a portion of the
insurance required by this Section 9.5. 

        10.    TERM AND TERMINATION    

        10.1. This
Agreement shall be effective as of the Effective Date and, unless earlier terminated or extended as provided herein, shall continue through December 31,
2004. The term of this Agreement may be extended by MedImmune for up to three (3) additional periods of three (3) years each provided it gives written notice to Cardinal Health of its
intention to extend the term at least six (6) months prior to expiration in each case. 

        10.2. MedImmune
may terminate this Agreement at any time upon (CONFIDENTIAL TREATMENT REQUESTED) prior written notice to Cardinal Health; provided, however that in the event
that MedImmune terminates because it desires to undertake Secondary Production at MedImmune's own facility, MedImmune shall provide Cardinal Health with (CONFIDENTIAL TREATMENT REQUESTED) prior
written notice of termination of this Agreement. 

        10.3. [Reserved.]

        10.4. Either
Party shall have the right to immediately terminate this Agreement if the other Party files a petition in bankruptcy, or enters into an agreement with its
creditors, or applies for or consents to the appointment of a receiver or trustee, or makes an assignment for the benefit of creditors, or suffers or permits the entry of an order adjudicating it to
be bankrupt or insolvent, provided that such bankruptcy is not discharged within thirty (30) days. 

        10.5. If
either Party materially breaches any of the provisions of this Agreement and such breach is not cured within (CONFIDENTIAL TREATMENT REQUESTED) after the giving of
written notice, the Party claiming the breach shall have the right to terminate this Agreement. 

        10.6. Either
Party may terminate this Agreement upon (CONFIDENTIAL TREATMENT REQUESTED) written notice and without penalty in the event of failure to obtain FDA approval for 

15

 

the
Product in the United States or any license, permit or certificate required by any governmental or regulatory agency is not approved and/or issued by any applicable Agency, provided that such
other party may no longer appeal such decision, reapply or otherwise pursue such permit, license or certificate. 

        10.7. In
the event of expiration or termination of this Agreement, (i) MedImmune shall pay for all completed Product whether or not MedImmune takes delivery of such
Product, (ii) MedImmune shall bear no responsibility for the payment of any Secondary Production not completed prior to termination of this Agreement, (iii) Cardinal Health shall
promptly, at MedImmune's request and expense, destroy or return to a location to be specified by MedImmune, any remaining inventory of Materials and Product to MedImmune, unless such termination shall
have been as a result of termination or a breach of this Agreement by Cardinal Health, in which case such Primary Product and Materials shall be returned or destroyed at Cardinal Health's expense, and
MedImmune shall reimburse Cardinal Health for the cost of all Materials so returned; (iv) each Party shall promptly return all Proprietary Information (as described in Article 12) to the
Disclosing Party; and (v) MedImmune shall remove the MedImmune Production Equipment from the MedImmune Facility in accordance with the Facility Production Agreement. 

        10.8. Termination
of this Agreement shall not affect any rights or claims of either Party that accrued prior to the date of such termination. The rights and obligations of
each of the Parties under the provisions of Sections 6.8, 6.9, 6.11, 6.13, 6.15, 10.7, 10.8, 10.9, 13.4, and Articles 9, 11 and 12 shall survive the termination or expiration of this Agreement for any
reason. 

        10.9. Upon
termination of this Agreement, the Facility Reservation Agreement shall terminate, and the consequences of such termination shall be as set forth in
Section 10 of that Agreement. 

        11.    DISPUTE RESOLUTION.    Any controversy, claim, or dispute (the
"Dispute") between the Parties arising out of or relating to this Agreement, or the breach thereof, shall be submitted to the chief executive officer of
Cardinal Health and the Chief Executive Officer of MedImmune for twenty (20) days for resolution. If the Dispute has not been resolved in such period, the Dispute shall be resolved through
arbitration before three (3) arbitrators. Such arbitration shall take place in Philadelphia and shall proceed in accordance with the Commercial Arbitration Rules of the American Arbitration
Association ("Commercial Rules") and the laws of Pennsylvania without regard to the provisions thereof concerning conflict of laws. Within thirty
(30) calendar days of either Party making a demand for arbitration, MedImmune and Cardinal Health shall each select one (1) arbitrator. A third arbitrator shall be selected by the
arbitrators selected by the Parties within ninety (90) days of the demand for arbitration. In the event that either Party shall fail to appoint its arbitrator, or the two arbitrators selected
by the Parties fail to appoint the third arbitrator, in either case within the prescribed time period, then either Party may apply to the American Arbitration Association for the appointment of such
arbitrator. The determination of a majority of the panel of arbitrators shall be the decision of the arbitrators and shall be binding regardless of whether on of the Parties fails or refuses to
participate in the arbitration; said determination shall be enforceable by any court of competent jurisdiction. Each Party shall pay for the arbitrator it selects with the cost of the third arbitrator
being divided equally between the Parties. All other costs related to the arbitration shall be borne by the Party incurring such costs, unless otherwise agreed to by the Parties. 

        12.    CONFIDENTIALITY    

        12.1.    Definition.    As used in this Agreement, the term Proprietary Information shall mean any information, either
enabling or disabling, including the terms of this Agreement, any batch record, any order or other commercial relationship between the Parties, know-how, trade secrets, research, data,
process, technique, algorithm, program design, drawing, formula, experimental design or test data relating to any research project, work in process, future development, scientific, manufacturing,
marketing, business plan, financial or personnel matter relating to the disclosing Party ("Disclosing  

16

 

 Party"), its present or future products, sales, suppliers, customers, employees, investors or business, whether in oral, written graphic or electronic form and whether received
from the Disclosing Party or a third party. The term Proprietary Information shall include, without limitation, (a) any cost information related to the manufacture of Product, and
(b) the Packaging Specifications for Product, each of which has previously been disclosed to Cardinal Health. 

        12.2.    Obligation.    During the term of this Agreement and for a period of ten (10) years thereafter, the
receiving Party (the "Receiving Party") shall maintain in confidence all Proprietary Information, as defined in Section 12.1 above, and shall not
use, disclose or grant use of such Proprietary Information except as expressly authorized by this Agreement. The Receiving Party may disclose Proprietary Information, as authorized hereunder, only to
those employees, agents or consultants of the Receiving Party reasonably requiring access. The Receiving Party shall use the standard of care which is practical
to ensure that such employees do not disclose or make any unauthorized use of Proprietary Information. The Receiving Party shall promptly notify the Disclosing Party upon discovery of any unauthorized
use of disclosure of Proprietary Information. 

        12.3.    Exclusions.    The term Proprietary Information shall not be deemed to include information which the
Receiving Party can demonstrate by competent written proof (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party, generally known or available,
(b) is known by the Receiving Party at the time of receiving such information as evidenced by its records, (c) is hereafter furnished to the Receiving Party by a third party, as a matter
of right and without restriction on disclosure, or (d) is the subject of a written permission to disclose provided by the Disclosing Party. Further, the obligations of confidentiality under
this Article 12 shall not apply to the extent that the Receiving Party is required to disclose Proprietary Information in support of applying for, obtaining or maintaining a product approval or
other filings with, by an order or regulation of, an Agency or in the course of litigation or other legal or administrative proceedings, provided that in all cases the Receiving Party shall to the
extent permitted give the other Party prompt notice of the pending disclosure and shall cooperate in such other party's attempts, at such other party's sole expense, to seek an order maintaining the
confidentiality of the Proprietary Information. 

        13.    FEES & PAYMENT TERMS    

        13.1    Definitions.    

        (a)   "Unit" means one syringe. 

        (b)   "Production Year" means the period of time commencing on January 1 of that year and ending on December 31
of that same year (e.g., Production Year 2004 means January 1, 2004 to December 31, 2004). 

        13.2    Secondary Production Price.    Subject to adjustment as set forth in Section 13.3 and subject to the
minimum payment requirements set forth in Section 13.4, the Unit price for Secondary Production ("Price") shall be $(CONFIDENTIAL TREATMENT
REQUESTED) for Production Year 2003, $(CONFIDENTIAL TREATMENT REQUESTED) for Production Year 2004, and the Price for Production Year 2005 and beyond shall be established by Cardinal Health based on
volume and line yield per minute and shall not exceed the amounts set forth in Appendix 3. A fee for inspection shall be in addition to the Price and shall be as set forth in
Section 13.4 below. 

        13.3    Price Adjustment.    The Price as set forth in Section 13.2 above and Appendix 3 shall be
subject to adjustment as set forth below. 

        (a)   Materials Component Adjustment. In the event MedImmune supplies Cardinal Health with Materials (excluding cartons,
inserts and labels) Cardinal Health shall reduce the Price by the cost attributable to the particular Materials supplied by MedImmune. In the event that the cost of Materials increases, Cardinal
Health shall provide MedImmune written notice of the increase on or before 

17

 

October 1,
the increase shall be effective the following January 1 and Cardinal Health shall provide reasonable supporting documentation for such increase. 

        (b)   Labor Component Adjustment. The labor component of the Price is based on hourly employee wages, salaried employee wages,
and fringe benefits for both hourly and salaried employees. Price increases based on hourly wage increases shall not exceed increases stipulated in the collective bargaining agreement between Cardinal
Health and its hourly employees, or if there is no collective bargaining agreement, shall not exceed increases in the Consumer Price Index. Price increases based on salaried employee wage increases
shall be limited to increases in the Consumer Price Index. Price increases based on fringe benefit cost increases shall be based on actual benefit cost increases. In the event that the Labor component
of the Price increases, Cardinal Health shall provide MedImmune written notice of the increase on or before October 1, the increase (subject to the maximums set forth above) shall be effective
the following January 1 and Cardinal Health shall provide reasonable supporting documentation for such increase. Notwithstanding the foregoing, if Cardinal Health provides evidence reasonably
acceptable to MedImmune demonstrating unexpected or unforeseeable inflationary labor costs which are not captured in this Agreement, the parties agree to negotiate in good faith appropriate pricing in
the context of such unexpected or unforeseen events and MedImmune shall not unreasonably withhold its consent to such increase. 

        (c)   Minimum Payments. As consideration for Cardinal Health's commitment to have its facility, equipment and personnel
available to perform Secondary Production, during the Term of this Agreement, it shall be entitled to minimum payments on an annual basis. In the event that the Price for Units invoiced to MedImmune
during a Production Year totals less than the minimum payment amount set forth below for the Production Year, then MedImmune shall pay Cardinal Health the difference. 

	Production Year
 
	 	Minimum Payment

	2003	 	$(CONFIDENTIAL TREATMENT REQUESTED)
	2004	 	$(CONFIDENTIAL TREATMENT REQUESTED)
	2005	 	$(CONFIDENTIAL TREATMENT REQUESTED)
	2006	 	$(CONFIDENTIAL TREATMENT REQUESTED)
	2007	 	$(CONFIDENTIAL TREATMENT REQUESTED)
	2008	 	$(CONFIDENTIAL TREATMENT REQUESTED)
	2009	 	$(CONFIDENTIAL TREATMENT REQUESTED)
	2010	 	$(CONFIDENTIAL TREATMENT REQUESTED)
	2011	 	$(CONFIDENTIAL TREATMENT REQUESTED)
	2012	 	$(CONFIDENTIAL TREATMENT REQUESTED)
	 	 	$(CONFIDENTIAL TREATMENT REQUESTED)

        Cardinal
Health shall invoice MedImmune for this amount within (CONFIDENTIAL TREATMENT REQUESTED) days following the end of the Production Year. For the avoidance of doubt, if the Price
for Units invoiced to MedImmune during a Production Year exceeds the minimum payment amount set forth above for that Production Year, then MedImmune will not be required to make an end of year payment
to Cardinal Health under this Section 13.3(c). 

        13.4    Fees for Visual Inspection.    The Parties agree that automatic inspection of the Secondary Production will be
used to the extent possible, but if booth personnel are required for visual inspection, Cardinal Health will notify MedImmune and MedImmune may either (a) supply its own inspectors at no
additional cost or (b) MedImmune will pay Cardinal Health the cost for Cardinal Health's employees and support during the validation phase of Secondary Production (other than for validation of
Cardinal Health Production Equipment) and for inspection costs based on the hourly rate per employee during the applicable Production Year as set forth in  Appendix 4. Cardinal Health will invoice
MedImmune monthly for any such expenses. Cardinal Health acknowledges that costs associated with 

18

 

validation
of Cardinal Health Production Equipment will be the responsibility of Cardinal Health and on-going employee training related to Secondary Production will also be at Cardinal
Health's expense. 

        13.5    Payment Procedures.    

        (a)   Cardinal
Health shall invoice MedImmune (CONFIDENTIAL TREATMENT REQUESTED) following completion of Secondary Production and submission of the packaging batch record. All
proper Cardinal Health invoices will be payable by MedImmune (CONFIDENTIAL TREATMENT REQUESTED) days after date of the invoice. Failure by MedImmune to make a payment when due shall be deemed to be a
material breach for purposes of Section 10.5. 

        (b)   All
payments made by MedImmune to Cardinal Health under this Article 13 will be made in U.S. dollars by check or by wire transfer to an account designated by
Cardinal Health. 

        (c)   In
the event Product is determined to be non-conforming pursuant to the procedure under Section 7.3, any amount paid by MedImmune for such rejected
Product shall be credited to MedImmune's account within (CONFIDENTIAL TREATMENT REQUESTED) days. 

        13.6    Recordkeeping.    Cardinal Health shall keep accurate records in sufficient detail to permit the determination
of all invoices and fees payable, credits due, and units of Product packaged hereunder and, within ten (10) days following a request by MedImmune shall permit either MedImmune or its agents, to
examine during ordinary business hours such records for the purpose of verifying the accuracy of any such invoices, fees, credits and units. 

        14.    GENERAL    

        14.1.    Interpretation.    The construction, validity, and performance of this Agreement shall be governed in all
respects by the laws of Pennsylvania, exclusive of its conflict-of-law provisions. This Agreement was negotiated by sophisticated parties at arms' length and neither party
shall be construed as the drafting party against which the Agreement could be construed. 

        14.2.    Force Majeure.    Failure or omission by either Party hereto in the performance of any obligation of this
Agreement (other than obligations to pay amounts due hereunder) shall not be deemed a breach of this Agreement and shall not create any liability if the same shall arise from any cause or causes
beyond the reasonable control of such Party, including, but not limited to, (other than the failure or refusal of the FDA to approve the Product for sale), fire, storm, flood, earthquake, accident,
acts of the public enemy, war, terrorism, rebellion, insurrection, riot, and invasion. In the event of Force Majeure, the Party affected shall promptly notify the other Party, and shall use reasonable
commercial efforts to eliminate, cure or overcome such event and to resume performance of its obligation hereunder. Notwithstanding the foregoing, should any event of Force Majeure as defined above
prevent the Parties from performing the Agreement for a period exceeding three (3) months, the non-affected Party shall have the right to terminate this Agreement without further
notice. It is expressly agreed by the Parties that strikes, lockouts and other labor problems shall not be deemed incidences of Force Majeure, and in such situations, Cardinal Health agrees to use its
reasonable commercial efforts to comply with its obligations under this Agreement. 

        14.3.    Notices.    Any notice or consent required to be given by either Party shall be given in writing addressed to
the Party for whom it is intended at the address set forth in the preamble to this Agreement (or, in the case of MedImmune, notices on or after January 1, 2004, should be sent to One MedImmune
Way, Gaithersburg, Maryland 20878, Attn: Legal Affairs) or such other address as such Party may designate in writing, and sent by overnight courier or certified mail, return receipt requested or
confirmed facsimile. Such facsimile to be sent to (215) 281-9190 in the case of Cardinal Health and to MedImmune Legal Affairs at (301) 527-4214 in the case of
MedImmune. In the case of Cardinal Health, a copy of notice shall be sent to Cardinal Health, Inc., 7000 Cardinal Place, Dublin, Ohio 43017, Attn: Vice President and Associate General Counsel,
Pharmaceutical Technologies & Services. 

19

 

        14.4.    Waiver.    The failure on the part of any Party to exercise or enforce rights conferred upon it hereunder
shall not be deemed to be a waiver of any such rights nor operate to bar the exercise or enforcement thereof at any time or times thereafter. 

        14.5.    Assignability.    Neither Party may assign this Agreement or any rights granted hereunder in whole or in part
(other than a transaction involving or between Cardinal Health and Cardinal Health, Inc. or other subsidiaries or divisions or Cardinal Health, Inc., provided such assignee is an
Affiliate of Cardinal Health, Inc.) without the prior written consent of the other Party, except either Party may assign this Agreement in whole or in part to one of its Affiliates or to the
successor(s) to or assignee(s) of all or substantially all of the part of its business to which this Agreement relates. The Parties agree that any
change of ownership or control of either MedImmune or Cardinal Health shall not affect the Parties' rights and obligations under this Agreement. 

        14.6.    Entire Agreement.    This Agreement and the Schedules, Exhibits and Appendices hereto, constitute the entire
agreement between the Parties concerning the subject matter hereof and supersede all prior agreements or understandings whether written or oral between the Parties with respect to the subject matter
hereof. 

        14.7.    Titles.    The headings appearing at the beginning of the numbered Articles hereof have been inserted for
convenience only and do not constitute any part of this Agreement. 

        14.8.    Publicity and Press Releases.    Neither party will make any press release or other public disclosure
regarding this Agreement or the transactions contemplated hereby without the other party's express prior written consent, except as required under applicable law or by any Agency, in which case the
party required to make the press release or public disclosure shall use commercially reasonable efforts to obtain the approval of the other party as to the form, nature and extent of the press release
or public disclosure prior to issuing the press release or making the public disclosure. 

        14.9.    Relationship of the Parties.    Notwithstanding any provision hereof, for all purposes of this Agreement each
Party shall be and act as an independent contractor and not as partner, joint venture, or agent of the other and shall not bind not attempt to bind the other to any contract. 

        14.10.    Modifications.    No changes or modifications or waivers are to be made to this Agreement unless evidenced
in writing and signed for and on behalf of both Parties. 

        14.11.    Severability.    In the event that any provision of this Agreement shall be determined to be illegal or
unenforceable, that provision will be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable. 

        15.    NON-SOLICITATION OF EMPLOYEES    

        15.1. MedImmune
agrees that, during the term of this Agreement and for a period of three (3) years thereafter, MedImmune will not, directly or indirectly, solicit for
employment or hire any employee of Cardinal Health. 

        15.2. Cardinal
Health agrees that, during the term of this Agreement and for a period of three (3) years thereafter, Cardinal Health will not, directly or indirectly,
solicit for employment or hire any employee of MedImmune. 

        16.    MICHIGAN LICENSE.    

        16.1 Cardinal
Health accepts: 

        (a)   It
may use the Vaccine only in Secondary Production; and 

        (b)   Except
as set forth in this Agreement, Cardinal Health shall not provide any Vaccine, Primary Product or Product, or derivatives thereof to any third party, unless
instructed to do so by an authorized officer of MedImmune. Cardinal Health shall limit access to the Primary Product supplied 

20

 

by
MedImmune to those employees reasonably requiring such access for Secondary Production, which employees are governed by Cardinal Health's customary confidentiality obligations. 

        16.2 MedImmune
shall: 

        (a)   use
every reasonable effort to honor and observe its obligations under the Michigan Agreement and shall not act or fail to act in any way which might jeopardize or cause
to be terminated the Michigan Agreement; and, 

        (b)   promptly
notify Cardinal Health of any amendment to the Michigan Agreement that affects Cardinal Health's performance under this Agreement; and, 

        (c)   make
every reasonable effort to notify Cardinal Health in writing of the expiration or termination of the Michigan Agreement at least six weeks prior to either event. 

        16.3 Cardinal
Health will use every reasonable effort to conduct Secondary Production and to Store Materials, Stored Materials and Product in accordance with all applicable
government laws and regulations. 

        16.4 MedImmune,
on Michigan's behalf, may request from Cardinal Health at reasonable times and in reasonable quantities Product at a cost equal to Cardinal Health's cost for
production of Product as it may desire, provided that Cardinal Health shall be under no obligation under this sub-clause or otherwise to produce extra batches of Product solely or
substantially to meet Michigan's requirements. Ay requirements of Michigan shall be supplied from Product being produced for MedImmune with MedImmune being solely responsible for apportioning such
part thereof to Michigan as MedImmune sees fit. MedImmune shall promptly pay to Cardinal Health the difference between the cost of Product supplied to Michigan hereunder and the price of Product as
set forth in Section 13.1. 

        16.5 Cardinal
Health acknowledges Michigan's warranty disclaimer and limitation of liability contained in the Michigan Agreement but makes no assessment or admission of its
validity or reasonableness. Notwithstanding such, Cardinal Health will not make any statements, representations or warranties inconsistent with such warranty disclaimer or limitation of liability
other than in pursuance or prosecution of its own rights and remedies. 

        16.6 Cardinal
Health will indemnify Michigan, its fellows, officers, employees and agents for and against any and all claims, damages, losses and expenses of any nature
resulting from, but not limited to, death, personal injury, illness or property damage, arising directly and solely as a result of; 

        (a)   any
Secondary Production, use or other disposition by Cardinal Health of the Vaccine, Primary Product or Product; 

        (b)   the
use by Cardinal Health, its agents or employees of Vaccine, Primary Product, or Product made or used by Cardinal Health; 

        (c)   the
use, handling, storage or disposal of Vaccine, any derivatives, Primary Product, or Product by Cardinal Health; or 

        (d)   the
unauthorized and negligent use by Cardinal Health of any know-how, or technical data sub-licensed to MedImmune from Michigan (and of which
know-how and technical data MedImmune has expressly notified Cardinal Health as being sub-licensed to MedImmune by Michigan) or developed by Cardinal Health pursuant to
Secondary Production, where but only where such claims, damages, losses and expenses are a direct consequence of the negligence of Cardinal Health, its agents or employees. 

        16.7 Cardinal
Health shall not use the name of Michigan in publicity or advertising concerning the Product, Primary Product or the Vaccine without the prior written consent
of Michigan, such consent not to be unreasonably or arbitrarily withheld nor delayed. Reports in scientific literature and 

21

 

presentations
of joint research and development work are not considered publicity for the purpose of this clause. 

        IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their respective duly authorized officers or
representatives as of the date first above written. 

	 	 	CARDINAL HEALTH 406, INC.
	

 	
 	

By:	
 	

/s/  RENARD JACKSON      
 Name: Renard Jackson

Title: EVP Sales, Bus. Dev.
	

 
	
 	
MEDIMMUNE VACCINES, INC.

	

 	
 	

By:	
 	

/s/  EDWARD V. ARCURI      
 Name: Edward V. Arcuri

Title: Sr. VP Manufacturing

Cardinal Health Parent Guaranty:  

        Cardinal Health, Inc., the parent company of Cardinal Health, hereby irrevocably and unconditionally guarantees the performance by Cardinal Health of the
contractual obligations set forth in this Agreement. This guaranty is an absolute, unconditional and continuing guaranty of the full performance of all obligations of Cardinal Health under this
Agreement. MedImmune is not obligated to first seek performance of any of the contractual obligations by Cardinal Health before seeking enforcement of this guaranty by Cardinal Health, Inc. 

CARDINAL HEALTH, INC.  

	By:	 	/s/  RENARD JACKSON      
	 	 
	 	 	Name: Renard Jackson

Title: EVP Sales, Bus. Dev.	 	 

22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]